Medically Reviewed | Last Updated: May 2026 | Based on peer-reviewed clinical trial data Key TakeawaysGLP-1 medications like semaglutide can
Medically reviewed | Last updated: May 2026 | Reading time: approx. 12 min Key TakeawaysGLP-1 receptor agonists are not FDA-approved
Based on 2025 clinical data If you’ve been researching GLP-1 medications, you’ve almost certainly hit this wall: injections and pills
Last updated: May 2026 | Medical Disclaimer: This article is for informational purposes only. It is not a substitute for
KEY TAKEAWAYS In the SURMOUNT-1 trial, 4% to 6% of tirzepatide users reported hair shedding vs. 1% on placebo. The
KEY TAKEAWAYS Tirzepatide causes real but proportionate lean mass loss: about 25% of total weight lost is lean tissue, matching
Medically Reviewed | Last Updated: May 2026 Key TakeawaysTirzepatide carries an FDA boxed warning for thyroid C-cell tumours based on
Key Takeaways Pancreatitis occurred in fewer than 0.5% of tirzepatide users across multiple large clinical trials, a rate statistically similar
KEY TAKEAWAYSGLP-1 medications can cause significant lean muscle loss alongside fat during rapid weight reduction. Consuming 1.2 to 1.6 grams
Medically reviewed framework | Last updated: April 2026 Key TakeawaysGLP-1 hair loss is almost always telogen effluvium, a temporary shedding
